Do you want to read an article? Please log in or register.
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study
Inflammatory Bowel Disease
Related content
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
Lancet Gastroenterol Hepatol.
Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO
doi: 10.1016/S2468-1253
COMMENTED
Inflammatory Bowel Disease
Long-Term Efficacy And Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
J Crohns Colitis
Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G
doi: 10.1093/ecco-jcc/jjab012
RECOMMENDED
Gallbladder and Biliary Diseases
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
Lancet Gastroenterol Hepatol.
Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, MacConell L, Shapiro D
doi: 10.1016/S2468-1253(19)30094-9.
Inflammatory Bowel Disease
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial
J Intern Med.
Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KE, Tveit KS, Lorentzen M, Berset IP, Fevang BT, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK
doi: 10.1111/joim.12880.
COMMENTED
Esophagus Diseases
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis
★ 3
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
doi: 10.1016/j.cgh.2020.03.036.
Inflammatory Bowel Disease
IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease
J Crohns Colitis.
Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S
doi: 10.1093/ecco-jcc/jjz110.
RECOMMENDED
Inflammatory Bowel Disease
Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S
doi: 10.1093/ecco-jcc/jjaa027.
Inflammatory Bowel Disease
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
Lancet Gastroenterol Hepatol.
Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G
doi: 10.1016/S2468-1253(20)30188-6.
Inflammatory Bowel Disease
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Lancet Gastroenterol Hepatol.
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group
doi: 10.1016/S2468-1253(19)30012-3.